Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.

Female with PCOS experiences receding and thinning hair, wants dutasteride instead of spironolactone. Discusses desire to reduce DHT without losing libido.

The user experienced side effects from finasteride and found improved mood and performance with DHT, but it worsened hair loss. They are considering options like TRT, HCG, and topical treatments like Saw Palmetto, but struggle with balancing hair preservation and functionality.

PP405 may revive dormant hair follicles, and DHT blockers like finasteride or dutasteride could maintain new hair. Combining PP405 with minoxidil might be optimal, but long-term effects and continuous use are uncertain.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

BPC-157 may promote hair growth by increasing angiogenesis, similar to how Minoxidil works, though no direct research confirms this yet. Users report combining BPC-157 with Minoxidil and finasteride for better results, but concerns about long-term safety exist.

The post discusses a hair loss treatment regimen using saw palmetto, pumpkin seed oil extract, EGCG (green tea) extract, grape seed oil extract, rosemary oil extract, and Zix. The user plans to use these DHT-blockers and 5AR inhibitors for six months and report the results.

Finasteride use led to increased body hair and shedding, possibly due to Reflex Hyperandrogenicity. The user is considering trying Finasteride again and seeks advice on whether to proceed.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

PP405 is criticized for overhyped claims and cherry-picked data, with doubts about its effectiveness compared to minoxidil and finasteride. Many users express skepticism, emphasizing the need for more comprehensive trial results.

The conversation discusses a transgender individual's successful hair loss treatment over 1.5 years using 2.5mg oral minoxidil, 5mg finasteride, and 8mg weekly injectable estradiol valerate. Some users debate the appropriateness of this approach within the group's goals, while others support the individualized treatment and its additional benefits for transgender individuals.

PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.

Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.

A transwoman shared her 11-month progress using hormone replacement therapy (HRT), finasteride, and minoxidil, reporting significant hair regrowth and satisfaction with the results. The discussion included various perspectives on HRT, its effects on hair and sexual function, and personal experiences with similar treatments.

The conversation discusses how different factors can stimulate type 1 and type 2 isoforms of 5-alpha reductase, which are enzymes linked to hair loss. Specific treatments mentioned include oral Dutasteride and topical Finasteride.

Dutasteride raises scalp testosterone by 99%, which may not be ideal for those sensitive to all androgens. Some argue finasteride's balancing act might be better, while others believe dutasteride is superior for hair regrowth.

High cost of studying 3α-Hydroxysteroid dehydrogenase in hair loss led to suggestions of crowdfunding for research. Users discussed using Procyanidin B2/melatonin topical treatment and tracking funds with blockchain.

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.

Latanoprost at 0.1% concentration is used to increase hair counts, often mixed with Minoxidil and Finasteride. Users report noticeable results in about 3 months.

Concerns about the potential systemic effects and safety of PP405 for hair loss, with discussions on its comparison to existing treatments like finasteride and minoxidil. Users express skepticism about untested research chemicals and emphasize the importance of clinical trials to ensure safety and efficacy.

PP405 is viewed skeptically, with some seeing it as overhyped and potentially ineffective compared to existing treatments like minoxidil and finasteride. While it shows some promise in activating dormant hair follicles, many believe it won't replace hair transplants or significantly outperform current options.

New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.

White rice may lower DHT and potentially cause symptoms similar to post-finasteride syndrome. The user experienced muscle wasting, depression, and other symptoms after consuming large amounts of white rice.

PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.

The user visited a trichologist due to ineffective topical finasteride treatment for hair loss. The trichologist recommended a new regimen including a two-month course of locoidon (cortisone 0.1%), followed by a solution containing minoxidil, hydrocortisone butirrate, estrone, progesterone, tocopherol acetate, trichosol, and transcutol.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

Minoxidil increases blood supply to the scalp, strengthening dormant follicles and extending the growth phase, but may increase scalp activity that can be countered with DHT blockers. Women experiencing side effects from finasteride or dutasteride for hair loss might consider alternatives like estrogen, especially if on birth control.

The user reported high testosterone and estradiol levels within range, but unexpectedly high DHT levels after using finasteride and dutasteride for hair loss. Another person suggested the dutasteride might be fake or a bad batch and recommended using the branded Avodart.

A 32-year-old male started taking 0.5mg of finasteride daily for hair thinning and, after 8 weeks, experienced a 70% reduction in DHT and an increase in estradiol; he is currently in the shedding phase of treatment and questioning if the dosage is correct based on his DHT levels. He began with a lower dose due to already low normal testosterone and DHT levels.

Breezula shows promising hair growth results, with up to 539% increase in hair count compared to placebo, and regulatory submissions are planned in the US and EU. Users are cautiously optimistic, noting the potential for Breezula to replace finasteride by targeting DHT without systemic effects.